On today’s Medication Minute, we will be discussing gabapentin, including its pharmacology, use in management of psychiatric diagnoses, and it’s more recent growing potential for abuse. Gabapentin is a gamma-aminobutyric acid analog that is was approved for use as an antiepileptic in 1993 and for post-herpetic neuralgia in 2004, but is also used off label for alcohol withdrawal symptoms, diabetic neuropathy, fibromyalgia, restless legs syndrome, and other types of neuropathic pain.
- Sadock, Benjamin James. Sadock, Virginia Alcott. Ruiz, Pedro. Kaplan & Sadock’s Synopsis of Psychiatry: Behavioral Sciences/clinical Psychiatry. Philadelphia: Lippincott Williams & Wilkins, 2015. Print.
- Smith, Rachel V., et al. “Gabapentin misuse, abuse, and diversion: a systematic review.” Addiction, vol. 111, no. 7, 2016, pp. 1160-1174., doi:10.1111/add.13324.
- Reccoppa, Lawrence, et al. “Gabapentin abuse in inmates with prior history of cocaine dependence.” American Journal on Addictions, vol. 13, no. 3, 2004, pp. 321-323., doi:10.1080/10550490490460300.
- “Gabapentin: Drug information.” com. Web. 18 October 2018.
- Peckham, Alyssa M. et al. “Prevalence of gabapentin abuse: comparison with agents with known abuse potential in a commercially insured US population.” Clinical Drug Investigation, 37, no. 8, 2018, pp. 763-773., doi:10/1007/s40261-017-0530-3. 20 October 2018.
- Berlin, Rachel K., et al. “Gabapentin Therapy in Psychiatric Disorders.” The Primary Care Companion For CNS Disorders, 2015, doi:10.4088/pcc.15r01821. 24 October 2018.